OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

OpenAI is investing more in the pharmaceutical industry. The company has acquired Orchestra Bio, a startup that helps drug companies organize and manage the process of developing medicines. Orchestra Bio will become part of Rosalind, OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers study questions about biology and chemistry. Rosalind Workbench connects these AI abilities to scientific data and tools.

Together, the teams aim to build AI agents that connect scientific discoveries with clinical trials, decisions, and the next steps in drug development. Their goal is to help new medicines reach patients faster. Developing a drug in the United States takes an average of 10 to 15 years. Scientific challenges are one reason the process takes so long. Another is that teams often use separate systems that do not work well together. Teams inside a company and outside partners also spend a lot of time going back and forth.

Orchestra's AI agents are designed to reduce this workload. They can track clinical trials, point out which schedules may be affected when something goes wrong, such as a failed batch of medicine during production, and suggest possible next steps. This could give scientists more time to make decisions and focus on their research. OpenAI already works with Novo Nordisk and Moderna on pharmaceutical research that uses AI. The companies did not reveal the financial terms of the deal.